New semantics in GoPubMed and European biotech start-ups

Transinsight has announced the launch of GoPubMed.com version 4.0, the semantic search engine for the life sciences with significantly improved features.
  • Increased Speed: GoPubMed 4.0 is ten times faster than its predecessor, now handling millions of documents in seconds.
  • Intelligent search: Never miss a document. The new interactive filtering process reduces millions of documents to a handful of key papers in just a few clicks. The Web 2.0 query processing helps by suggesting search ideas as you type.
  • More document sources: The GoPubMed.com website offers searches on PubMed and the Web at no cost. The professional version of GoPubMed PRO is designed to include intranet searches and patents.
  • Improve GoPubMed: The public website GoPubMed.com allows users to manually annotate and verify papers including their background information. The platform has already about 60.000 enthusiastic helping hands. GoPubMed shows the semantic path to the future: community generated ontologies and so improves the quality of search results.

"GoPubMed PRO for corporate semantic searches can handle multiple ontologies represented in many languages. The integrated semi-automated ontology generation tool helps to create ontologies of unknown domains much faster than doing them by hand. Local intranet and desktop searches will help our customers extend the power of the semantic search technology to their local information pools which helps reduce the time needed for manual information retrieval significantly. Cutting down the average hours spent weekly (12.4) on information searches to a little more than 1 hour can be directly expressed in terms money spent." explains Dr. Liliana Barrio-Alvers, CTO at Transinsight. "This is what our customers appreciate: greater efficiency that translates into faster and higher returns on their investments."

The judges of the European Venture Summit, which took place 1 & 2 December 2008 in Düsseldorf, Germany, ranked Transinsight and GoPubMed PRO as one of the Top 5 presenters in Biotech.

GoPubMed builds on cutting edge research developed in cooperation with TU Dresden in the EU project Sealife and is supported by INNO-WATT. For more information go to: www.GoPubMed.com.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honored with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...